- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05628207
Evaluation of the SCALED (SCaling AcceptabLE cDs)
August 10, 2026 updated by: University of Minnesota
Evaluation of the SCALED (SCaling AcceptabLE cDs) Approach for the Implementation of Interoperable CDS for Venous Thromboembolism Prevention - CDS Data
This project will adapt a currently deployed Clinical Decision Support (CDS) system to deliver a VTE prevention guideline for adult patients with traumatic brain injury (TBI).
We believe this is an ideal PCOR use case given PCORI's continued effort to combat VTE in trauma and our experience previously implementing this guideline.
The Our overall goal is to successfully scale, evaluate, and maintain an interoperable TBI CDS across 7 total institutions.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Estimated)
15000
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Christopher Tignanelli, MD,MS
- Phone Number: 612 625 7911
- Email: ctignane@umn.edu
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- Recruiting
- University of Minnesota
-
Contact:
- Nicholas Lemke
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
N/A
Sampling Method
Non-Probability Sample
Study Population
All patients age 18 and older admitted with a TBI will be eligible for inclusion.
Description
Inclusion Criteria:
- age 18 and older
- admitted with a TBI
Exclusion Criteria:
- Patients who die within 24 hours of hospital admission and patients documented as "comfort cares" during the first 72 hours of hospitalization or with mild TBI will be excluded from final analysis.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
4 hospitals using CDS TBI
healthcare system leveraging the rigorous approach, SCALED (SCaling AcceptabLE cDs), to guide CDS scaling across the system in VTE prevention.
|
There is no intervention, the hospitals will adopt a CDS system which prompts users to follow best practice guidelines.
|
|
3 hospitals not using CDS TBI (control)
healthcare system not leveraging the rigorous approach, SCALED (SCaling AcceptabLE cDs), to guide CDS scaling across the system in VTE prevention.
|
There is no intervention, the hospitals will not use the CDS system.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
primary effectiveness outcome
Time Frame: 2 years and a half
|
VTE event rate
|
2 years and a half
|
|
Evaluate implementation strategy guided by the EPIS Implementation
Time Frame: 2 years and a half
|
the number of patients that received treatment according to the best practice guideline and the % adherence to the guideline per site
|
2 years and a half
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 16, 2023
Primary Completion (Estimated)
September 30, 2026
Study Completion (Estimated)
September 30, 2026
Study Registration Dates
First Submitted
November 16, 2022
First Submitted That Met QC Criteria
November 16, 2022
First Posted (Actual)
November 28, 2022
Study Record Updates
Last Update Posted (Actual)
August 12, 2026
Last Update Submitted That Met QC Criteria
August 10, 2026
Last Verified
August 1, 2026
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Vascular Diseases
- Cardiovascular Diseases
- Wounds and Injuries
- Embolism and Thrombosis
- Craniocerebral Trauma
- Trauma, Nervous System
- Brain Injuries
- Thromboembolism
- Brain Injuries, Traumatic
- Venous Thromboembolism
- Health Services Administration
- Quality of Health Care
- Outcome Assessment, Health Care
- Outcome and Process Assessment, Health Care
- Watchful Waiting
Other Study ID Numbers
- HRP-595
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.